20 PARK PLAZA, BOSTON, MA
News
CervoMed Reinforces Neflamapimod's Benefits for DLB at AD/PD™ 2026
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Neflamapimod Elected for Inclusion in UK EXPERTS-ALS Platform Designed to Prioritize Promising Treatments for Amyotrophic Lateral Sclerosis
Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Financial Results, Press Release
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRRN14A
Contested Proxy Solicitation Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Submission Upload
Correspondence